MedPath

Comparing Chemoprevention Approaches for School-based Malaria Control

Phase 4
Completed
Conditions
Malaria,Falciparum
Anemia in Children
Interventions
Registration Number
NCT05244954
Lead Sponsor
University of Maryland, Baltimore
Brief Summary

This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent screening and treatment (IST) - students will receive treatment if they have a positive high sensitivity rapid diagnostic test (RDT). Arm 2: Intermittent preventive treatment (IPT) - all students will receive treatment. Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, gametocyte carriage and gametocyte density, anemia, cognitive function and educational testing, as well as infection prevalence in student's households to assess the impact on transmission.

Detailed Description

Students will be enrolled in a single primary school in Machinga District, Malawi. The intervention will be conducted every 6-weeks during the two school terms which coincide with peak malaria transmission. Students in the IPT are and those that test positive in the IST arm will be treatment with dihydroartemisinin-piperaquine (DP) (females less than 10 years old and all males) or chloroquine (females 10 years old or older).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
746
Inclusion Criteria

Students (enrolled in the primary intervention)

  • Currently enrolled in the study school
  • Plan to attend the study school for the remainder of the school year
  • Parent/guardian available to provide written informed consent Household members (enrolled in the Household Prevalence survey)
  • Slept in the household for most nights in the last month
  • Age 6 months or older
  • For minors, parent/guardian available to provide written informed consent
Exclusion Criteria

Students (enrolled in the primary intervention)

  • Current evidence of severe malaria or danger signs
  • Known adverse reaction to the study drugs
  • History of cardiac problems or fainting
  • Taking medications known to prolong QT
  • Family history of prolonged QT
  • Girls 10 years old and older with epilepsy or psoriasis Household members (enrolled in the Household Prevalence survey)
  • Household with more than one school-age child enrolled in the study
  • Current evidence of severe malaria or danger signs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intermittent Screening and Treatment (IST)ChloroquineStudents will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
Intermittent Preventive Treatment (IPT)ChloroquineAll students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
Intermittent Screening and Treatment (IST)Dihydroartemisinin-PiperaquineStudents will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
Intermittent Preventive Treatment (IPT)Dihydroartemisinin-PiperaquineAll students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
Primary Outcome Measures
NameTimeMethod
P. falciparum gametocyte carriage6-8 weeks after the last intervention

detected by q-rtPCR (binary)

P. falciparum infection6-8 weeks after the last intervention

detected by polymerase chain reaction (PCR, binary)

Secondary Outcome Measures
NameTimeMethod
Number of participant with anemia6-8 weeks after the last intervention

World Health Organization age-sex definitions (binary)

Total parasite density6-8 weeks after the last intervention

log transformed (continuous)

Gametocyte density6-8 weeks after the last intervention

log transformed (continuous)

Rate of clinical malariafrom the first intervention to 6-8 weeks after the last intervention

cumulative incidence

P. falciparum prevalence among household members6-8 weeks after the last intervention

detected by PCR

Mean hemoglobin concentration6-8 weeks after the last intervention

g/dL (continuous)

Trial Locations

Locations (1)

Kamuzu University of Health Sciences

🇲🇼

Blantyre, Malawi

© Copyright 2025. All Rights Reserved by MedPath